Skip to content

Bicara Therapeutics BCAX Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$56.21M-52.6%-$37.39M-78.4%-$36.33M-108%-$27.39M-60.6%-$36.85M-195%
$44K+132%$43K+187%$24K+60.0%$19K+46.2%$19K+46.2%
$5.86M+69.7%$4.45M+39.9%$3.61M+77.9%$3.49M+236%$3.45M+201%
-$37.51M-33.5%-$23.89M+20.5%-$29.25M-69.8%-$25.59M-98.3%-$28.11M-92.7%
$60K$238K+495%$42K+425%$0-100%$0-100%
$100.94M-$82.33M-205,730%-$236.12M$0$0-100%
$163.35M+35,410%$31.23M$436K-99.9%$135K-81.6%$460K+236%
$226.78M+920%-$74.99M-216%-$264.93M-184%-$25.46M-109%-$27.65M-92.1%
-$37.57M-33.7%-$24.12M+19.8%-$29.29M-70.0%-$25.59M-98.0%-$28.11M-92.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Bicara Therapeutics generate?
Bicara Therapeutics (BCAX) generated -$116.2M in operating cash flow over the trailing twelve months.
What is Bicara Therapeutics's free cash flow?
After $340.0K of capital expenditures, Bicara Therapeutics's free cash flow was -$116.6M over the trailing twelve months, down 32.0% year over year.
Where does Bicara Therapeutics's cash flow data come from?
Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.